AstraZeneca Stomach Cancer Drug Trial: 53% Lower Death Risk, But PFS Misses
The AstraZeneca stomach cancer drug trial showed a 53% lower risk of death in later-line patients, but progression-free survival missed significance.
The AstraZeneca stomach cancer drug trial showed a 53% lower risk of death in later-line patients, but progression-free survival missed significance.